Current diagnosis and treatment of visceral leishmaniasis

References

• Joshi A, Narain JP, Prasittisuk C et al. Can visceral leishmaniasis be eliminated from Asia? J. Vector Borne Dis.45(2), 105–111 (2008).
   PubMedGoogle Scholar
• Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl. Trop. Dis.2(10), e313 (2008).
   PubMed Web of Science ®Google Scholar
• Romero GA, Boelaert M. Control of visceral leishmaniasis in latin America – a systematic review. PLoS Negl. Trop. Dis.4(1), e584 (2010).
   PubMed Web of Science ®Google Scholar
• den Boer M, Davidson RN. Treatment options for visceral leishmaniasis. Expert Rev. Anti Infect. Ther.4(2), 187–197 (2006).
   PubMedGoogle Scholar
• Lukes J, Mauricio IL, Schönian G et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl Acad. Sci. USA104(22), 9375–9380 (2007).
   PubMed Web of Science ®Google Scholar
• Maurício IL, Stothard JR, Miles MA. The strange case of Leishmania chagasi. Parasitol. Today16(5), 188–189 (2000).
   PubMedGoogle Scholar
• Khalil EA, Zijlstra EE, Kager PA, El Hassan AM. Epidemiology and clinical manifestations of Leishmania donovani infection in two villages in an endemic area in eastern Sudan. Trop. Med. Int. Health7, 35–44 (2002).
   PubMed Web of Science ®Google Scholar
• Kafetzis DA. An overview of paediatric leishmaniasis. J. Postgrad. Med.49(1), 31–38 (2003).
   PubMedGoogle Scholar
• Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis.3(2), 87–98 (2003).
   PubMed Web of Science ®Google Scholar
• Alvar J, Aparicio P, Aseffa A et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin. Microbiol. Rev.21(2), 334–359 (2008).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Laboratory diagnosis of visceral leishmaniasis. Clin. Diagn. Lab. Immunol.9, 951–958 (2002).
   PubMedGoogle Scholar
• Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, Ethiopia. Trop. Med. Int. Health8, 733–739 (2003).
   PubMed Web of Science ®Google Scholar
• Bentwich Z. Concurrent infections that rise the HIV viral load. J. HIV Ther.8, 72–75 (2003).
   PubMedGoogle Scholar
• Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishmaniasis in HIV infection. J. Postgrad. Med.49, 39–49 (2003).
   PubMedGoogle Scholar
• Fernandez-Cotarelo MJ, Abellan Martinez J, Guerra Vales JM et al. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin. Infect. Dis.37, 973–977 (2003).
   PubMedGoogle Scholar
• Riera C, Fisa R, Lopez P et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow up. Eur. J. Clin. Microbiol. Infect. Dis.23, 899–904 (2004).
   PubMed Web of Science ®Google Scholar
• Deniau M, Canavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann. Trop. Med. Parasitol.297(Suppl. 1), 115–133 (2003).
   Google Scholar
• Delgado J, Macias J, Pineda JA et al. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients. Am. J. Trop. Med. Hyg.61, 766–769 (1999).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Dejenie A, Assefa Y et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin. Infect. Dis.43(3), 357–364 (2006).
   PubMed Web of Science ®Google Scholar
• Roberts MT. Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br. Med. Bull.75–76, 115–130 (2006).
   PubMedGoogle Scholar
• Singh S. New developments in diagnosis of leishmaniasis. Indian J. Med. Res.123(3), 311–330 (2006).
   PubMed Web of Science ®Google Scholar
• da Silva MR, Stewart JM, Costa CH. Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg.72(6), 811–814 (2005).
   PubMed Web of Science ®Google Scholar
• Abass EM, Mansour D, el Harith A. Demonstration of agglutinating anti Leishmania antibodies in lymph node aspirate for confirmation of kala-azar serodiagnosis. J. Med. Microbiol.56(Pt 9), 1256–1258 (2007).
   PubMedGoogle Scholar
• Reus M, García B, Vázquez V, Morales D, Fuster M, Sola J. Visceral leishmaniasis: diagnosis by ultrasound-guided fine needle aspiration of an axillary node. Br. J. Radiol.78(926), 158–160 (2005).
   PubMedGoogle Scholar
• Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol.5(11), 873–882 (2007).
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh RK, Bimal SK et al. Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a Phase III diagnostic accuracy study. Trop. Med. Int. Health12(2), 284–289 (2007).
   PubMedGoogle Scholar
• Iqbal J, Hira PR, Saroj G et al. Imported visceral leishmaniasis: diagnostic dilemmas and comparative analysis of three assays. J. Clin. Microbiol.40(2), 475–479 (2002).
   PubMed Web of Science ®Google Scholar
• Cruz I, Chicharro C, Nieto J et al. Comparison of new diagnostic tools for management of pediatric Mediterranean visceral leishmaniasis. J. Clin. Microbiol.44(7), 2343–2347 (2006).
   PubMed Web of Science ®Google Scholar
• Pedras MJ, de Gouvêa Viana L, de Oliveira EJ, Rabello A. Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.102(2), 172–178 (2008).
   PubMedGoogle Scholar
• BenAbderrazzak S, Saghrouni F, Gaïed-Meksi S et al. Immunochromatographic RK39 strip test in the serodiagnosis of visceral leishmaniasis in Tunisia. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Chappuis F, Rijal S, Soto A, Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. Br. Med. J.333(7571), 723 (2006).
   PubMed Web of Science ®Google Scholar
• Boelaert M, El-Safi S, Hailu A et al. Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans. R. Soc. Trop. Med. Hyg.102(1), 32–40 (2008).
   PubMed Web of Science ®Google Scholar
• Mandal J, Khurana S, Dubey ML, Bhatia P, Varma N, Malla N. Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg.79(1), 76–78 (2008).
   PubMed Web of Science ®Google Scholar
• Oliveira E, Pedras MJ, de Assis IE, Rabello A. Improvement of direct agglutination test (DAT) for laboratory diagnosis of visceral leishmaniasis in Brazil. Trans. R. Soc. Trop. Med. Hyg.103(12), 1279–1281 (2009).
   PubMedGoogle Scholar
• ter Horst R, Tefera T, Assefa G, Ebrahim AZ, Davidson RN, Ritmeijer K. Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia. Am. J. Trop. Med. Hyg.80(6), 929–934 (2009).
   PubMed Web of Science ®Google Scholar
• Terán-Angel G, Schallig H, Zerpa O, Rodríguez V, Ulrich M, Cabrera M. The direct agglutination test as an alternative method for the diagnosis of canine and human visceral leishmaniasis. Biomedica27(3), 447–453 (2007).
   PubMedGoogle Scholar
• Al-Nahhas SA, Al-Taweel AA, Al-Taweel MA. Assessment of the direct agglutination test, fast agglutination screening test, and rK39 dipstick test for the sero-diagnosis of visceral leishmaniasis in Syria. Saudi Med. J.29(9), 1250–1254 (2008).
   PubMedGoogle Scholar
• Mikaeili F, Fakhar M, Sarkari B, Motazedian MH, Hatam G. Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain. Iran J. Immunol.4(2), 116–121 (2007).
   PubMedGoogle Scholar
• Jacquet D, Boelaert M, Seaman J et al. Comparative evaluation of freeze-dried and liquid antigens in the direct agglutination test for serodiagnosis of visceral leishmaniasis (ITMA-DAT/VL). Trop. Med. Int. Health11(12), 1777–1784 (2006).
   PubMed Web of Science ®Google Scholar
• Hailu A, Schoone GJ, Diro E et al. Field evaluation of a fast anti-Leishmania antibody detection assay in Ethiopia. Trans. R. Soc. Trop. Med. Hyg.100(1), 48–52 (2006).
   PubMedGoogle Scholar
• Silva ES, Schoone GJ, Gontijo CM, Brazil RP, Pacheco RS, Schallig HD. Application of direct agglutination test (DAT) and fast agglutination screening test (FAST) for sero-diagnosis of visceral leishmaniasis in endemic area of Minas Gerais, Brazil. Kinetoplastid. Biol. Dis.4, 4 (2005).
   PubMedGoogle Scholar
• Islam MZ, Itoh M, Takagi H et al. Enzyme-linked immunosorbent assay to detect urinary antibody against recombinant rKRP42 antigen made from Leishmania donovani for the diagnosis of visceral leishmaniasis. Am. J. Trop. Med. Hyg.79(4), 599–604 (2008).
   PubMedGoogle Scholar
• Sarkari B, Hatam GR, Mikaeili F, Sadeghi H, Ebrahimi S. A comparative study of antigen and antibody detection in visceral leishmaniasis using serum and urine-based ELISA. Trop. Biomed.25(2), 96–99 (2008).
   PubMedGoogle Scholar
• Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, Ali N. Immune responses in kala-azar. Indian J. Med. Res.123(3), 245–266 (2006).
   PubMedGoogle Scholar
• Mansour D, Abass EM, El Mutasim M, Mahamoud A, El Harith A. Use of a newly developed beta-mercaptoethanol enzyme-linked immunosorbent assay to diagnose visceral leishmaniasis in patients in eastern Sudan. Clin. Vaccine Immunol.14(12), 1592–1595 (2007).
   PubMedGoogle Scholar
• Saha S, Mazumdar T, Anam K et al.Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis. J. Clin. Microbiol.43(3), 1269–1277 (2005).
   PubMedGoogle Scholar
• Maalej IA, Chenik M, Louzir H et al. Comparative evaluation of ELISAs based on ten recombinant or purified Leishmania antigens for the serodiagnosis of Mediterranean visceral leishmaniasis. Am. J. Trop. Med. Hyg.68(3), 312–320 (2003).
   PubMed Web of Science ®Google Scholar
• Mohapatra TM, Singh DP, Sen MR, Bharti K, Sundar S. Compararative evaluation of rK9, rK26 and rK39 antigens in the serodiagnosis of Indian visceral leishmaniasis. J. Infect. Dev. Ctries4(2), 114–117 (2010).
   PubMedGoogle Scholar
• Farajnia S, Darbani B, Babaei H, Alimohammadian MH, Mahboudi F, Gavgani AM. Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of visceral leishmaniasis in Iran. Parasitology135(9), 1035–1041 (2008).
   PubMedGoogle Scholar
• Romero HD, Silva Lde A, Silva-Vergara ML et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am. J. Trop. Med. Hyg.81(1), 27–33 (2009).
   PubMed Web of Science ®Google Scholar
• Zijlstra EE, Nur Y, Desjeux P, Khalil EA, El-Hassan AM, Groen J. Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop. Med. Int. Health6(2), 108–113 (2001).
   PubMed Web of Science ®Google Scholar
• Ravindran R, Anam K, Bairagi BC et al. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect. Immun.72(2), 863–870 (2004).
   PubMed Web of Science ®Google Scholar
• Kumar D, Srividya G, Verma S et al. Presence of anti-Lepp12 antibody: a marker for diagnostic and prognostic evaluation of visceral leishmaniasis. Trans R. Soc. Trop. Med. Hyg.102(2), 167–171 (2008).
   PubMedGoogle Scholar
• Sakru N, Korkmaz M, Ozbel Y, Ertabaklar H, Sengul M, Toz SO. Investigation of asymptomatic visceral leishmaniasis cases using western blot in an endemic area in Turkey. New Microbiol.30(1), 13–18 (2007).
   PubMedGoogle Scholar
• de Souza Dias S, da Costa Pinheiro PH, Katz S, dos Santos MR, Barbiéri CL. A recombinant cysteine proteinase from Leishmania (Leishmania) chagasi suitable for serodiagnosis of American visceral leishmaniasis. Am. J. Trop. Med. Hyg.72(2), 126–132 (2005).
   PubMedGoogle Scholar
• Sundar S, Maurya R, Singh RK et al. Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J. Clin. Microbiol.44(1), 251–253 (2006).
   PubMed Web of Science ®Google Scholar
• Monno R, Giannelli G, Rizzo C, De Vito D, Fumarola L. Recombinant K39 immunochromatographic test for diagnosis of human leishmaniasis. Future Microbiol.4(2), 159–170 (2009).
   PubMedGoogle Scholar
• Rouf MA, Rahman ME, Islam MN, Islam MN, Ferdous NN, Hossain MA. Sensitivity, specificity and predictive values of immunochromatographic strip test in diagnosis of childhood kala-azar. Mymensingh Med. J.18(1 Suppl.), S1–S5 (2009).
   PubMedGoogle Scholar
• Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O’keeffe C, Davidson RN. Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am. J. Trop. Med. Hyg.74(1), 76–80 (2006).
   PubMedGoogle Scholar
• Das ML, Deb M, Karki BM et al. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal. Southeast Asian J. Trop. Med. Public Health38(4), 619–625 (2007).
   PubMedGoogle Scholar
• Salotra P, Sreenivas G, Ramesh V, Sundar S. A simple and sensitive test for field diagnosis of post kala-azar dermal leishmaniasis. Br. J. Dermatol.145(4), 630–632 (2001).
   PubMed Web of Science ®Google Scholar
• Singh D, Pandey K, Das VN et al. Novel noninvasive method for diagnosis of visceral leishmaniasis by rK39 testing of sputum samples. J. Clin. Microbiol.47(8), 2684–2685 (2009).
   PubMedGoogle Scholar
• Veeken H, Ritmeijer K, Seaman J, Davidson R. Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop. Med. Int. Health8(2), 164–167 (2003).
   PubMed Web of Science ®Google Scholar
• Chappuis F, Mueller Y, Nguimfack A et al. Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J. Clin. Microbiol.43(12), 5973–5977 (2005).
   PubMedGoogle Scholar
• Deniau M, Cañavate C, Faraut-Gambarelli F, Marty P. The biological diagnosis of leishmaniasis in HIV-infected patients. Ann. Trop. Med. Parasitol.97(Suppl. 1), 115–133 (2003).
   PubMed Web of Science ®Google Scholar
• Rabello A, de Assis TM, da Costa Braga A et al. Validation of the Rapid Test IT-LEISH® for the diagnosis of human visceral leishmaniasis in Brazil. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Canavate C, Flores M, Pradas MA, Gonzalez R, Nieto J, Singh S. Use of SIGNAL®-KA kit for the diagnosis of visceral leishmaniasis in Spain. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Singh S, Dey A, Sivakumar R. Applications of molecular methods for Leishmania control. Expert Rev. Mol. Diagn.5(2), 251–265 (2005).
   PubMed Web of Science ®Google Scholar
• Diro E, Techane Y, Tefera T et al. Field evaluation of FD-DAT, rK39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans. R. Soc. Trop. Med. Hyg.101(9), 908–914 (2007).
   PubMed Web of Science ®Google Scholar
• Malaei S, Mohebali M, Akhoundi B, Zarei Z. Evaluation of latex agglutination test (Katex) for the detection of urinary antigens in human visceral leishmaniasis. J. Tehran Un. Med. Sci.4, 101–108 (2006).
   Google Scholar
• Hatam GR, Ghatee MA, Hossini SM, Sarkari B. Improvement of the newly developed latex agglutination test (Katex) for diagnosis of visceral leishmaniasis. J. Clin. Lab. Anal.23(4), 202–205 (2009).
   PubMedGoogle Scholar
• Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol.45(1), 21–25 (2007).
   PubMed Web of Science ®Google Scholar
• Prina E, Roux E, Mattei D, Milon G. Leishmania DNA is rapidly degraded following parasite death: an analysis by microscopy and real-time PCR. Microbes Infect.9(11), 1307–1315 (2007).
   PubMed Web of Science ®Google Scholar
• Arora SK, Gupta S, Bhardwaj S, Sachdeva N, Sharma NL. An epitope-specific PCR test for diagnosis of Leishmania donovani infections. Trans. R. Soc. Trop. Med. Hyg.102(1), 41–45 (2008).
   PubMedGoogle Scholar
• Foulet F, Botterel F, Buffet P et al. Detection and identification of Leishmania species from clinical specimens by using a real-time PCR assay and sequencing of the cytochrome B gene. J. Clin. Microbiol.45(7), 2110–2115 (2007).
   PubMed Web of Science ®Google Scholar
• Motazedian M, Fakhar M, Motazedian MH, Hatam G, Mikaeili F. A urine-based polymerase chain reaction method for the diagnosis of visceral leishmaniasis in immunocompetent patients. Diagn. Microbiol. Infect. Dis.60(2), 151–154 (2008).
   PubMed Web of Science ®Google Scholar
• Vaish M, Babu YA, Mehrotra S et al. PCR based detection of Leishmania donovani in swab samples of visceral leishmaniasis: a non invasive diagnostic tool. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Turki-Mannoubi L, Kbaier-Hachemi H, Barhoumi M, Chakroun AS, Guizani I. A variant of DDRT-PCR using anchored mini-exon primers for identification of differentially expressed sequences in Leishmania infantum. Arch. Inst. Pasteur Tunis.85(1–4), 29–44 (2008).
   PubMedGoogle Scholar
• De Doncker S, Hutse V, Abdellati S et al. A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects. Trans. R. Soc. Trop. Med. Hyg.99(1), 25–31 (2005).
   PubMedGoogle Scholar
• Salam MA, Mondal D, Kabir M, Ekram AR, Haque R. PCR for diagnosis and assessment of cure in kala-azar patients in Bangladesh. Acta Trop.113(1), 52–55 (2010).
   PubMedGoogle Scholar
• Hochberg L, Rizvig F, Alan Magilla COL, Wagmana J, Gilmorea W. An overview of the Smart Leish real-time PCR diagnostic device. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Suliman K, Nasereddin A, Ereqat S, Abdeen Z. Reverse dot blot (RDB)-PCR for the diagnosis of old world leishmaniasis. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Mendez J, Brasov IE, Cortes E, Echazabal J, Weina PJ. Cellulose acetate electrophoresis (CAE) a vital technique in Leishmania diagnosis. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Deborggraeve S, Laurent T, Espinosa D et al. A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J. Infect. Dis.198(10), 1565–1572 (2008).
   PubMedGoogle Scholar
• Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop. Med. Int. Health5, 312–317 (2000).
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother.6(16), 2821–2829 (2005).
   PubMed Web of Science ®Google Scholar
• Jha TK. Drug unresponsiveness and combination therapy for kala azar. Indian J. Med. Res.123, 389–398 (2006).
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis.31, 1104–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J. Med. Res.123(3), 275–288 (2006).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Davidson RN. Royal Society of Tropical Medicine and Hygiene joint meeting with Medecins Sans Frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins sans frontieres interventions against kala-azar in the Sudan, 1989–2003. Trans R. Soc. Trop. Med. Hyg.97(6), 609–613 (2003).
   PubMed Web of Science ®Google Scholar
• Das VN, Siddiqui NA, Pandey K et al. A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India. Ther. Clin. Risk Manag.5(1), 117–124 (2009).
   PubMedGoogle Scholar
• Khalil EA, el Hassan AM, Zijlstra EE et al. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann. Trop. Med. Parasitol.92(2), 151–158 (1998).
   PubMed Web of Science ®Google Scholar
• Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop. Med. Int. Health6(11), 849–854 (2001). Erratum in: Trop. Med. Int. Health7(3), 293 (2002).
   PubMed Web of Science ®Google Scholar
• Das VN, Ranjan A, Sinha AN et al. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. J. Assoc. Physicians India49, 609–613 (2001).
   PubMedGoogle Scholar
• den Boer ML, Alvar J, Davidson RN, Ritmeijer K, Balasegaram M. Developments in the treatment of visceral leishmaniasis. Expert Opin. Emerg. Drugs14(3), 395–410 (2009).
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004. Lancet Infect. Dis.5(12), 763–774 (2005).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar A, Mitra G et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J. Med. Res.128(1), 38–44 (2008).
   PubMed Web of Science ®Google Scholar
• Saha S, Mondal S, Ravindran R et al. IL-10- and TGF-b-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J. Immunol.179(8), 5592–5603 (2007).
   PubMed Web of Science ®Google Scholar
• Mueller Y, Nguimfack A, Cavailler P et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann. Trop. Med. Parasitol.102(1), 11–19 (2008).
   PubMed Web of Science ®Google Scholar
• Mueller Y, Mbulamberi DB, Odermatt P, Hoffmann A, Loutan L, Chappuis F. Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. Trop. Med. Int. Health14(8), 910–917 (2009).
   PubMedGoogle Scholar
• Singh RK, Pandey HP, Sundar S. Visceral leishmaniasis (kala-azar): challenges ahead. Indian J. Med. Res.123(3), 331–344 (2006).
   PubMed Web of Science ®Google Scholar
• Agrawal S, Rai M, Sundar S. Management of visceral leishmaniasis: Indian perspective. J. Postgrad. Med.51(Suppl. 1), S53–S57 (2005).
   PubMedGoogle Scholar
• Bern C, Adler-Moore J, Berenguer J et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis.43, 917–924 (2006).
   PubMed Web of Science ®Google Scholar
• Ritmeijer K, Ter Horst RCS, Davidson RN. Poor effectiveness of liposomal amphotericin-B (AmBisome) in HIV co-infected visceral leishmaniasia patients in Ethiopia. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Lima N. Experience of Médecins Sans Frontières after 1 year of using liposomal amphotericin B (AmBisome) treatment for Indian visceral leishmaniasis under routine programme conditions in Bihar, India. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med.362, 504 (2010).
   PubMed Web of Science ®Google Scholar
• Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans. R. Soc. Trop. Med. Hyg.101(1), 19–24 (2007).
   PubMed Web of Science ®Google Scholar
• Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL). Ann. Trop. Med. Parasitol.99(6), 563–569 (2005).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med.362, 504 (2010).
   PubMed Web of Science ®Google Scholar
• Laguna F, Videla S, Jiménez-Mejías ME et al. Spanish HIV-Leishmania Study Group. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J. Antimicrob. Chemother.52(3), 464–468 (2003).
   PubMed Web of Science ®Google Scholar
• López-Vélez R, Videla S, Márquez M et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J. Antimicrob. Chemother.53(3), 540–543 (2004).
   PubMed Web of Science ®Google Scholar
• Dietze R, Milan EP, Berman JD et al. Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion). Clin. Infect. Dis.17(6), 981–986 (1993).
   PubMed Web of Science ®Google Scholar
• Sundar S, Mehta H, Chhabra A et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin. Infect. Dis.42(5), 608–613 (2006).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, Shah A, Agrawal N, Rai M. Safety of a pre- formulated amphotericin B lipid emulsion for the treatment of Indian Kala-azar. Trop. Med. Int. Health13(9), 1208–1212 (2008).
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Agarwal D, Rai M, Agrawal N, Chakravarty J. Safety and efficacy of high-dose infusions of a preformed amphotericin B fat emulsion for treatment of Indian visceral leishmaniasis. Am. J. Trop. Med. Hyg.80(5), 700–703 (2009).
   PubMedGoogle Scholar
• Bodhe PV, Kotwani RN, Kirodian BG et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.93(3), 314–318 (1999).
   PubMed Web of Science ®Google Scholar
• Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami R. A curative immune profile one-week after treatment of Indian kala-azar patients predicts success with a short course liposomal amphotericin B therapy. PLoS Neglected Tropical Diseases (2010) (In Press).
   Google Scholar
• Sundar S, Rosenkaimer F, Makharia MK et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet352(9143), 1821–1823 (1998).
   PubMedGoogle Scholar
• Sundar S, Olliaro P. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther. Clin. Risk Manag.3(5), 733–740 (2007).
   PubMedGoogle Scholar
• Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med.347(22), 1739–1746 (2002).
   PubMed Web of Science ®Google Scholar
• Bhattacharya SK, Sinha PK, Sundar S et al. Phase 4trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis.196(4), 591–598 (2007).
   PubMed Web of Science ®Google Scholar
• Pandey BD, Pandey K, Kaneko O, Yanagi T, Hirayama K. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient. Am. J. Trop. Med. Hyg.80(4), 580–582 (2009).
   PubMed Web of Science ®Google Scholar
• Das VN, Pandey K, Verma N et al. Short report: development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg.80(3), 336–338 (2009).
   PubMed Web of Science ®Google Scholar
• Dorlo TP, van Thiel PP, Huitema AD et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother.52(8), 2855–2860 (2008).
   PubMed Web of Science ®Google Scholar
• Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg.84, 221–225 (1990).
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N. Engl. J. Med.356, 2571–2581 (2007).
   PubMed Web of Science ®Google Scholar
• Sundar S, Agrawal N, Arora R, Agarwal D, Rai M, Chakravarty J. Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment. Clin. Infect. Dis.49(6), 914–918 (2009).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin. Investig. Drugs17, 787–794 (2008).
   PubMed Web of Science ®Google Scholar
• Sundar S, Chatterjee M. Visceral leishmaniasis – current therapeutic modalities. Indian J. Med. Res.123(3), 345–352 (2006).
   PubMed Web of Science ®Google Scholar
• Dietze R, Carvalho SF, Valli LC et al. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg.65, 685–689 (2001).
   PubMed Web of Science ®Google Scholar
• van Griensven J, Balasegaram M, Meheus F, Alvar J, Lynen L, Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis.10(3), 184–194 (2010).
   PubMed Web of Science ®Google Scholar
• Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res.123(3), 399–410 (2006).
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg.77(1), 89–94 (2007).
   PubMed Web of Science ®Google Scholar
• Ramesh V, Kumar J, Kumar D, Salotra P. A retrospective study of intravenous sodium stibogluconate alone and in combinations with allopurinol, rifampicin, and an immunomodulator in the treatment of Indian post-kala-azar dermal leishmaniasis. Indian J. Dermatol. Venereol. Leprol.76(2), 138–144 (2010).
   PubMedGoogle Scholar
• Sundar S, Rai M, Chakravarty J et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis.47(8), 1000–1006 (2008).
   PubMed Web of Science ®Google Scholar
• Lackovic K, Parisot JP, Sleebs N et al. Inhibitors of leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small molecule chemical library. Antimicrob. Agents Chemother.54(5), 1712–1719 (2010).
   PubMedGoogle Scholar
• Mondal D, Singh SP, Kumar N et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl. Trop. Dis.3(1), e355 (2009).
   PubMed Web of Science ®Google Scholar
• Ostyn B, Vanlerberghe V, Picado A et al. Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop. Med. Int. Health13(8), 1073–1085 (2008).
   PubMed Web of Science ®Google Scholar
• Croft SL. PKDL – a drug related phenomenon? Indian J. Med. Res.128(1), 10–11 (2008).
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar A, Mitra G et al. Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India. Indian J. Med. Res.128(1), 38–44 (2008).
   PubMed Web of Science ®Google Scholar
• Davis AJ, Murray HW, Handman E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol.20(2), 73–76 (2004).
   PubMedGoogle Scholar
• Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob. Agents Chemother.44(6), 1494–1498 (2000).
   PubMed Web of Science ®Google Scholar
• Bern C, Courtenay O, Alvar J. Of cattle, sand flies and men: a systematic review of risk factor analyses for South Asian visceral leishmaniasis and implications for elimination. PLoS Negl. Trop. Dis.4(2), e599 (2010).
   PubMedGoogle Scholar
• Werneck GL, Batista MS, Gomes JR, Costa DL, Costa CH. Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil. Infection31(3), 174–177 (2003).
   PubMed Web of Science ®Google Scholar
• Santos MA, Marques RC, Farias CA et al. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis. Rev. Soc. Bras. Med. Trop.35(6), 629–633 (2002).
   PubMedGoogle Scholar
• Romero HD, Silva Lde A, Silva-Vergara ML et al. Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area. Am. J. Trop. Med. Hyg.81(1), 27–33 (2009).
   PubMed Web of Science ®Google Scholar
• Mikaeili F, Fakhar M, Sarkari B, Motazedian MH, Hatam G. Comparison of serological methods (ELISA, DAT and IFA) for diagnosis of visceral leishmaniasis utilizing an endemic strain. Iran J. Immunol.4(2), 116–121 (2007).
   PubMedGoogle Scholar
• el Mutasim M, Mansour D, Abass EM, Hassan WM, el Harith A. Evaluation of a glycerol-preserved antigen in the direct agglutination test for diagnosis of visceral leishmaniasis at rural level in eastern Sudan. J. Med. Microbiol.55(Pt 10), 1343–1347 (2006).
   PubMedGoogle Scholar
• Sundar S, Singh RK, Maurya R et al. Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans. R. Soc. Trop. Med. Hyg.100(6), 533–537 (2006).
   PubMedGoogle Scholar
• Bimal S, Das VNR, Sinha PK et al. Usefulness of the direct agglutination test in the early detection of subclinical Leishmania donovani infection: a community-based study. Ann. Trop. Med. Parasitol.99(8), 743–749 (2005).
   PubMed Web of Science ®Google Scholar
• Yeganeh F, Barkhordari F, Omidi M et al. Cloning and expression of Leishmania major superoxide dismutase B1: a potential target antigen for serodiagnosis of Leishmaniasis. Iran J. Immunol.6(3), 130–140 (2009).
   PubMedGoogle Scholar
• Viana LDG, de Assis TSM, Orsini M et al. Combined diagnostic methods identify a remarkable proportion of asymptomatic Leishmania (Leishmania) chagasi carriers who present modulated cytokine profiles. Trans. R. Soc. Trop. Med. Hyg.102(6), 548–555 (2008).
   PubMedGoogle Scholar
• Mansour D, Abass EM, Mahamoud A, el Harith A. Qualitative and semi-quantitative comparison of an rK39 strip test and direct agglutination test for detection of anti-Leishmania donovani antibodies in the Sudan. Iran J. Immunol.6(4), 208–215 (2009).
   PubMedGoogle Scholar
• Chappuis F, Rijal S, Jha UK et al. Field validity, reproducibility and feasibility of diagnostic tests for visceral leishmaniasis in rural Nepal. Trop. Med. Intl. Health.2(1), 31–40 (2006).
   Google Scholar
• Welch RJ, Anderson BL, Litwin CM. Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis. Clin. Vaccine Immunol.15(9), 1483–1484 (2008).
   PubMedGoogle Scholar
• Alam M, Shamsuzzaman A, Musa A et al. Antigen detection from urine of kala-azar cases by latex agglutination test. Mymensingh Med. J.17(1), 22–27 (2008).
   PubMedGoogle Scholar
• Fisa R, Riera C, López-Chejade P et al. Leishmania infantum DNA detection in urine from patients with visceral leishmaniasis and after treatment control. Am. J. Trop. Med. Hyg.78(5), 741–744 (2008).
   PubMedGoogle Scholar
• Brustoloni YM, Lima RB, da Cunha RV et al. Sensitivity and specificity of polymerase chain reaction in Giemsastained slides for diagnosis of visceral leishmaniasis in children. Mem. Inst. Oswaldo Cruz.102(4), 497–500 (2007).
   PubMedGoogle Scholar
• Aoun K, Chouihi E, Amri F, Mary C, Bouratbine A. Contribution of real-time PCR to the follow up of visceral leishmaniasis cases on treatment. Presented at: Worldleish4. Lucknow, India, 3–7 February 2009.
   Google Scholar
• Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M. Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am. J. Trop. Med. Hyg.79(6), 839–842 (2008).
   PubMed Web of Science ®Google Scholar
• Wasan KM, Wasan EK, Gershkovich P et al. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis. J. Infect. Dis.200(3), 357–360 (2009).
   PubMed Web of Science ®Google Scholar
• Tekwani BL, Walker LA. 8-aminoquinolines: future role as antiprotozoal drugs. Curr. Opin. Infect. Dis.19(6), 623–631 (2006).
   PubMed Web of Science ®Google Scholar
• Garnier T, Mäntylä A, Järvinen T, Lawrence J, Brown M, Croft S. In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J. Antimicrob. Chemother.60(4), 802–810 (2007).
   PubMed Web of Science ®Google Scholar
• Palit P, Ali N. Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis. Antimicrob. Agents Chemother.52(1), 374–377 (2008).
   PubMedGoogle Scholar
• Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, Uliana SR. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob. Chemother.63(2), 365–368 (2009).
   PubMed Web of Science ®Google Scholar
• Misra P, Sashidhara KV, Singh SP et al. 16a-Hydroxycleroda-3,13 (14)Z-dien-15,16-olide from Polyalthia longifolia: a safe and orally active antileishmanial agent. Br. J. Pharmacol.159(5), 1143–1150 (2010).
   PubMed Web of Science ®Google Scholar
• Palit P, Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani. J. Antimicrob. Chemother.61(5), 1120–1124 (2008).
   PubMed Web of Science ®Google Scholar
• Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J. Immunol.181(2), 1386–1398 (2008).
   PubMed Web of Science ®Google Scholar
• Reichwald C, Shimony O, Dunkel U, Sacerdoti-Sierra N, Jaffe CL, Kunick C. 2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype. J. Med. Chem.51(3), 659–665 (2008).
   PubMedGoogle Scholar
• Bakunov SA, Bakunova SM, Bridges AS et al. Synthesis and antiprotozoal properties of pentamidine congeners bearing the benzofuran motif. J. Med. Chem.52(18), 5763–5767 (2009).
   PubMedGoogle Scholar